Suh Jin-seok targets 700 billion won for Jimpenetra as shipments double Suh Jin-seok anticipates substantial growth for ...

The 2025 sales target is 50 percent higher than the 3.5 trillion won of annual revenue expected to be recorded this year, Celltrion Chairman Seo Jung-jin said in an investors relations meeting in ...

South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of ...

Korean pharmaceutical giant Celltrion on Tuesday pledged to achieve an annual growth rate of 30 percent and a return on equity of at least 7 percent by 2027, as part of its long-term initiative ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® (CT ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was ...

Celltrion’s plan to build a new drug product plant in Incheon's Songdo received approval from local authorities, the pharmaceutical company said Friday. The Incheon Free Economic Zone Authority ...